Demographic data of the patients in the study
| Infliximab (n = 53) | Etanercept (n = 6) | |
|---|---|---|
| Values are numbers of patients. Age and disease duration are presented with mean values. | ||
| *Antimalarials (3/1), minocycline (1/1), cyclosporin A (4), azathioprine (8), sulfasalazine (2), leflunomide (2), injectable gold (1). | ||
| DAS28, disease activity score for 28 joints; DMARD, disease modifying antirheumatic drug. | ||
| F/M | 43/10 | 5/1 |
| Age (years) | 54.8 | 48.3 |
| Range | (26 to 79) | (36 to 65) |
| Disease duration (years) | 13.8 | 9.1 |
| Range | (2 to 37) | (1.3 to 15) |
| Steroids (median dose 7.5 mg/d) | 30 (57%) | 3 (50%) |
| Methotrexate (5–20 mg/week) | 43 (81%) | 2 (33%) |
| Other DMARDs* | 19 (36%) | 2 (33%) |
| DAS28 at onset (mean (SEM)) | 5.9 (0.14) | 6.6 (0.52) |
| DAS28 at 54 weeks (mean (SEM)) | 3.7 (0.2) | 3.2 (0.33) |